Reliability and validity of the Atopic Dermatitis Symptom Score (ADSS)

Lee, J. Y.; Kim, M.; Yang, Hea-Kyoung; Kim, H. M.; Cho, Jungwan; Kim, Y.-M.; Lim, In Seok; Cheong, Hae-Kwan; Kim, H. S.; Sohn, Insuk; Kim, J.; Ahn, Kangmo

doi:10.1111/pai.12865

Cited by 18 publications

(15 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

Section: Mhealth In Allergic Diseasesmentioning

confidence: 99%

“…Other specific tools measure the impact of chronic skin diseases on sleep quality, using wearable sleep and/or itch trackers. Medication reminders or adherence apps remind patients to use their medication in time and might help to support action plans 71. Apps including information about the disease, playful information for children, treatment, living with the disease, videos, and patient stories can support self-management in patients.…”

mentioning

confidence: 99%

See 1 more Smart Citation

The role of mobile health technologies in allergy care: An EAACI position paper

Matricardi

Dramburg

Alvarez-Perea

et al. 2019

Allergy

109

111

View full text Add to dashboard Cite

Mobile health (mHealth) uses mobile communication devices such as smartphones and tablet computers to support and improve health‐related services, data and information flow, patient self‐management, surveillance, and disease management from the moment of first diagnosis to an optimized treatment. The European Academy of Allergy and Clinical Immunology created a task force to assess the state of the art and future potential of mHealth in allergology. The task force endorsed the “Be He@lthy, Be Mobile” WHO initiative and debated the quality, usability, efficiency, advantages, limitations, and risks of mobile solutions for allergic diseases. The results are summarized in this position paper, analyzing also the regulatory background with regard to the “General Data Protection Regulation” and Medical Directives of the European Community. The task force assessed the design, user engagement, content, potential of inducing behavioral change, credibility/accountability, and privacy policies of mHealth products. The perspectives of healthcare professionals and allergic patients are discussed, underlining the need of thorough investigation for an effective design of mHealth technologies as auxiliary tools to improve quality of care. Within the context of precision medicine, these could facilitate the change in perspective from clinician‐ to patient‐centered care. The current and future potential of mHealth is then examined for specific areas of allergology, including allergic rhinitis, aerobiology, allergen immunotherapy, asthma, dermatological diseases, food allergies, anaphylaxis, insect venom, and drug allergy. The impact of mobile technologies and associated big data sets are outlined. Facts and recommendations for future mHealth initiatives within EAACI are listed.

show abstract

Section: Mhealth In Allergic Diseasesmentioning

confidence: 99%

mentioning

confidence: 99%

The role of mobile health technologies in allergy care: An EAACI position paper

Matricardi

Dramburg

Alvarez-Perea

et al. 2019

Allergy

109

111

View full text Add to dashboard Cite

show abstract

“…Reliability and validity of the AD Symptom Score (ADSS) were studied in 307 children and adolescents with AD [17 ]. Parents or caregivers were asked to record daily symptoms of the patients (itching, sleep disturbance, erythema, dryness, oozing, and edema) using a scale of 0–4.…”

Section: Atopic Dermatitismentioning

confidence: 99%

Highlights and recent developments in skin allergy and related diseases in EAACI journals (2018)

Akdiş¹,

Bousquet²,

Grattan

et al. 2019

Clin Transl Allergy

View full text Add to dashboard Cite

The European Academy of Allergy and Clinical Immunology (EAACI) supports three journals: Allergy, Paediatric Allergy and Immunology as well as Clinical and Translational Allergy. The major goals of EAACI include (i) supporting health promotion in which the prevention of allergy and asthma plays a critical role and (ii) disseminating the knowledge of allergy to all stakeholders including the EAACI junior members. Substantial progress was made in 2018 in the identification of basic mechanisms of atopic dermatitis and urticaria and the translation of these mechanisms into clinics. Many large epidemiologic studies and meta-analyses have been the highlights of the last year.

show abstract

“…Parents used the Atopic Dermatitis Symptom Score (ADSS), a smartphone-based symptom diary designed to record their daily levels of itching, sleep disturbances, erythema, dryness, oozing, and edema on a scale of 0 to 4 [28]. Patients were considered to manifest AD symptoms when the symptom score was ≥2 for the sum of itching and sleep disturbance scores, plus at least two of the following on the same day: erythema, dryness, edema, or oozing [29].…”

Section: Ad Symptomsmentioning

confidence: 99%

Harmful Effects of Ambient Nitrogen Dioxide on Atopic Dermatitis: Comparison of Exposure Assessment Based on Monitored Concentrations and Modeled Estimates

Kim

et al. 2020

Atmosphere

Self Cite

View full text Add to dashboard Cite

Precise exposure assessment of air pollutants is crucial in epidemiologic studies to ensure valid estimates of health effects. We conducted a longitudinal study to evaluate the role of air quality monitoring (AQM) measurements and high-resolution modeling outcomes focusing on nitrogen dioxide (NO2) exposure and atopic dermatitis (AD). A total of 128 young children with AD in Seoul Metropolitan Area, Korea, were recruited as a panel. We estimated the participants’ exposure to NO2 for four months, from 1 April through 31 July 2014 based on (1) monitored levels from 60 AQM stations located at varying distances from residential areas (AQM station-based NO2, AQM-NO2) and (2) estimates from a community multi-scale air quality (CMAQ) modeling system with a high-resolution (1 × 1 km) (CMAQ-NO2). We then compared the effect of AQM-NO2 on AD symptoms with that of CMAQ-NO2. The average distance between the participants’ residences and the nearest AQM station was 2.03 ± 1.06 km, ranging from 0.28 km to 5.73 km. Based on AQM-NO2, the AD symptoms increased by 10.28% (95% confidence interval (CI): 3.24, 17.79) with an increase of 10 ppb of NO2. The effect estimates of CMAQ-NO2 were similar to those of AQM-NO2 when assessed in patients living within 3 km from the nearest AQM station. Even within 1 km, the CI estimate obtained from the CMAQ was much narrower than from AQM (44.18–49.54 vs. 7.02–64.75). However, the association of AQM-NO2 with AD symptoms of patients living beyond 3 km was not positive, whereas that of CMAQ-NO2 maintained positive. In conclusion, exposure to ambient NO2 is significantly associated with aggravation of AD symptoms in young children. In addition, our study suggests that exposure assessment of NO2 using measurement data obtained from monitoring stations far from residential locations can lead to misclassification bias.

show abstract

Reliability and validity of the Atopic Dermatitis Symptom Score (ADSS)

Abstract: The ADSS can be a useful tool for self-assessment of skin symptoms in children with AD.

Cited by 18 publications

References 30 publications

The role of mobile health technologies in allergy care: An EAACI position paper

The role of mobile health technologies in allergy care: An EAACI position paper

Highlights and recent developments in skin allergy and related diseases in EAACI journals (2018)

Harmful Effects of Ambient Nitrogen Dioxide on Atopic Dermatitis: Comparison of Exposure Assessment Based on Monitored Concentrations and Modeled Estimates

Contact Info

Product

Resources

About